Show simple item record

dc.contributor.authorGomes, F
dc.contributor.authorWong, M
dc.contributor.authorBattisti, NML
dc.contributor.authorKordbacheh, T
dc.contributor.authorKiderlen, M
dc.contributor.authorGreystoke, A
dc.contributor.authorLuciani, A
dc.date.accessioned2021-03-30T11:03:38Z
dc.date.available2021-03-30T11:03:38Z
dc.identifier.citationBritish journal of cancer, 2020, 123 (6), pp. 874 - 884
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4461
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/s41416-020-0986-4
dc.description.abstractImmunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer (NSCLC) from locally advanced disease to the metastatic setting. This approach has resulted in improved survival and a more favourable toxicity profile when compared with chemotherapy. Following the successful introduction of single-agent immunotherapy, current clinical trials are focusing on combination treatments with chemotherapy or radiotherapy or even other immunotherapeutic agents. However, most of the data available from these trials are derived from, and therefore might be more applicable to younger and fitter patients rather than older and often frail lung cancer real-world patients. This article provides a detailed review of these immunotherapy agents with a focus on the data available regarding older NSCLC patients and makes recommendations to fill evidence gaps in this patient population.
dc.formatPrint-Electronic
dc.format.extent874 - 884
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectLung Neoplasms
dc.subjectAntineoplastic Agents
dc.subjectImmunotherapy
dc.subjectRadioimmunotherapy
dc.subjectClinical Trials as Topic
dc.subjectImmunosenescence
dc.subjectImmune Checkpoint Inhibitors
dc.titleImmunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
dc.typeJournal Article
dcterms.dateAccepted2020-06-23
rioxxterms.versionAM
rioxxterms.versionofrecord10.1038/s41416-020-0986-4
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of cancer
pubs.issue6
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Breast Cancer Clinical Research
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Breast Cancer Clinical Research
pubs.publication-statusPublished
pubs.volume123
pubs.embargo.termsNo embargo
icr.researchteamBreast Cancer Clinical Research
icr.researchteamBreast Cancer Clinical Researchen_US
dc.contributor.icrauthorBattisti, Nicoloen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record